Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Triptorelin
Drug ID BADD_D02297
Description Triptorelin is a synthetic decapeptide agonist analog of luteinizing hormone releasing hormone (LHRH). Possessing greater potency than endogenous LHRH, triptorelin reversibly represses gonadotropin secretion. After chronic, continuous administration, this agent effects sustained decreases in LH and FSH production and testicular and ovarian steroidogenesis. Serum testosterone concentrations may fall to levels typically observed in surgically castrated men.
Indications and Usage Triptorelin is indicated for the palliative treatment of advanced prostate cancer.
Marketing Status Prescription
ATC Code L02AE04
DrugBank ID DB06825
KEGG ID D06247
MeSH ID D017329
PubChem ID 25074470
TTD Drug ID D03QRS
NDC Product Code 71161-106; 24338-150
Synonyms Triptorelin Pamoate | Pamoate, Triptorelin | Triptorelin Embonate | Embonate, Triptorelin | CL-118532 | CL 118532 | CL118532 | Trelstar | Triptorelin | LHRH, Trp(6)- | GnRH, Trp(6)- | LHRH, Tryptophyl(6)- | D-Trp-6-LH-RH | 6-D-Tryptophan-Luteinizing Hormone-Releasing Factor (Pig) | Wy-42462 | Wy 42462 | Wy42462 | AY-25650 | AY 25650 | AY25650 | Decapeptyl | Decapeptyl Trimestral | Trimestral, Decapeptyl | Decapeptyl LP | Decapeptyl Depot
Chemical Information
Molecular Formula C64H82N18O13
CAS Registry Number 57773-63-4
SMILES CC(C)CC(C(=O)NC(CCCN=C(N)N)C(=O)N1CCCC1C(=O)NCC(=O)N)NC(=O)C(CC2=CNC3=CC=CC=C32) NC(=O)C(CC4=CC=C(C=C4)O)NC(=O)C(CO)NC(=O)C(CC5=CNC6=CC=CC=C65)NC(=O)C(CC7=CN=CN7 )NC(=O)C8CCC(=O)N8
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
Not AvailableNot AvailableNot AvailableNot AvailableNot Available
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Seizure17.12.03.001--
Shock24.06.02.002--Not Available
Skin disorder23.03.03.007--Not Available
Somnolence19.02.05.003; 17.02.04.006--
Spinal cord compression17.10.01.006--
Testicular atrophy21.13.01.001; 05.05.02.004--Not Available
Testicular pain21.13.01.005--
Thrombophlebitis24.01.02.001--Not Available
Tinnitus17.04.07.004; 04.04.01.002--
Transient ischaemic attack24.04.06.005; 17.08.04.001--
Tumour flare16.32.03.001--Not Available
Urethral disorder20.07.01.002--Not Available
Urethral obstruction20.07.03.002--Not Available
Urinary retention20.02.02.011--
Urinary tract disorder20.08.01.001--Not Available
Urinary tract infection11.01.14.004; 20.08.02.001--
Urticaria23.04.02.001; 10.01.06.001--
Vascular purpura24.07.06.011; 23.06.01.008; 01.01.04.007--Not Available
Vertigo17.02.12.002; 04.04.01.003--
Vision blurred17.17.01.010; 06.02.06.007--
Visual impairment06.02.06.008--Not Available
Vomiting07.01.07.003--
Weight decreased13.15.01.005--
Weight increased13.15.01.006--
Musculoskeletal disorder15.03.01.004--Not Available
Pituitary haemorrhage05.03.04.005; 24.07.04.009; 17.08.01.019--Not Available
Dysstasia17.02.02.012--Not Available
Deep vein thrombosis24.01.02.003--Not Available
Acute coronary syndrome24.04.04.011; 02.02.02.015--Not Available
Lymphatic disorder01.09.01.003--Not Available
The 5th Page    First    Pre   5 6    Next   Last    Total 6 Pages